Osteosarcoma
Conditions
Keywords
Bone, Neoplasm, bone tissue, Acetylmuramyl-Alanyl-Isoglutamine
Brief summary
Trial evaluating the impact on efficacy of mifamurtide as add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response).
Detailed description
Multicentre, randomised, open-label, phase II trial, with 2 parallel groups. After pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable), patients presenting high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) will be randomised between 2 arms: * Control arm: post-operative chemotherapy alone (with regimens adapted to the age of patient) * Experimental arm : post-operative chemotherapy combined with mifamurtide This randomised trial is part of a study recruiting all patients ≤50 years old with a newly diagnosed high-grade osteosarcoma.
Interventions
COMBINATION_PRODUCTEI or M-API regimen depending on patient age
M-API regimen: One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days EI regimen : 5 course of EI, every 21 days
DRUGMifamurtide
48 doses overall over 36 weeks
Sponsors
UNICANCER
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 50 Years
Healthy volunteers
No
Inclusion criteria
Registration Criteria: 1. All newly diagnosed, biopsy-proven, high-grade osteosarcoma, whatever the initial extension of the disease 2. Age \>2 years and ≤50 years; 3. Normal haematological, renal, cardiac and hepatic functions 4. Planned neoadjuvant chemotherapy as follows: 1. Methotrexate-Etoposide-Ifosfamide (M-EI regimen) for patients ≤25 years 2. Doxorubicin-Cisplatin-Ifosfamide (API-AI regimen) for patients 26-50 years 5. Written informed consent from patients and/or their parents/guardians before enrolment and any study-related procedure 6. Affiliation to a social insurance regimen Inclusion Criteria: 1. Patient with a histologically proven, confirmed by experts pathologists panel (before surgery at the latest), high-grade osteosarcoma 2. Registered at diagnosis into the study 3. Primary tumour resected after pre-operative chemotherapy 4. Osteosarcoma classified as high risk because of at least one risk factor: 1. presence of distant metastases or skip metastases at diagnosis 2. and/or poor histological response to pre-operative chemotherapy (\>10% residual viable cells on the analysis of the primary tumour surgical specimen) 5. Pre-operative chemotherapy combining 1. Methotrexate-Etoposide-Ifosfamide (M-EI regimen) for patients ≤25 years 2. Doxorubicin-Cisplatin-Ifosfamide (API-AI regimen) for patients 26-50 years 6. Screening laboratory values must meet the following criteria (using CTCAE v4) and should be obtained within 7 days prior to randomisation: 1. Absolute neutrophil count ≥1.0 x 10⁹/L 2. Platelets ≥100 x 10⁹/L 3. Haemoglobin ≥8.0 g/mL 4. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x upper limit of normal (ULN) in the absence of liver metastases or ≤5 x ULN in the presence of liver metastases 5. Total Bilirubin ≤2 x ULN (except Gilbert Syndrome: \<3.0 mg/dL) or Total Bilirubin ≤5.0 x ULN in the presence of liver metastases 6. Creatinine clearance ≥60 mL/min/1.73 m² according to the Schwartz or Cockcroft formula according to patient's age 7. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) done within 7 days prior to randomisation 8. Provision of dated and signed written informed consent for the randomised trial prior to any study specific procedures, sampling and analyses. 9. Patient fit to undergo protocol treatment and follow-up 10. Affiliation to a social insurance regimen
Exclusion criteria
1. Low grade osteosarcoma, parosteal or periosteal osteosarcoma 2. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 3 years. 3. Osteosarcoma with multiple metastases for whom complete removal is not expected to be feasible even after shrinkage with chemotherapy 4. Progressive disease at any site under initial chemotherapy, confirmed before randomisation time, and not totally resected during surgery 5. Any medical condition precluding treatment with protocol chemotherapy 6. Fractional Shortening \<28% or left ventricular ejection fraction (LVEF) 50% before treatment (only for API post-operative chemotherapy) by echocardiogram or multigated acquisition (MUGA) scan 7. Pregnancy or breast-feeding 8. Hypersensitivity to the active substance or to any of the excipients 9. Concurrent use of immunodepressive treatment such as cyclosporine, tacrolimus or other calcineurin inhibitors 10. Concurrent use with high-dose non-steroidal anti-inflammatory drugs (NSAIDs, cyclooxygenase inhibitors) 11. Inflammatory or auto-immune disease, allergy or asthma requiring a chronic use of steroid treatment that cannot be stopped. 12. Patients with positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). 13. Patients with positive tests for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating active or chronic infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare event-free survival in the treatment arms | Expected average duration of 3 years from randomization | Event-free survival defined as the time duration from randomisation to time of first event (loco-regional or distant relapse or progression, second malignancy, death from any cause) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare overall survival in the treatment arms | Up to 10 years from randomization | Overall survival defined as the time duration from randomisation to death, whatever the cause of death |
| Compare actual and planned cumulative dose and dose intensity of mifamurtide | Up to 36 weeks from randomization (until end of treatment) | Calculation of actual cumulative dose and dose intensity compared to the planned treatment administration schedule |
| Compare the incidence of adverse events in the treatment arms | Up to 40 weeks from randomization (4 weeks after end of treatment) | Evaluation of toxicity (graded by NCI-CTCAE v4) |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORNathalie MD GASPAR, PhD
Gustave Roussy Cancer Campus
PRINCIPAL_INVESTIGATORSophie MD PIPERNO-NEUMANN, PhD
Institut Curie
Outcome results
None listed